口服糖皮质激素冲击治疗:临床实践的微调带来重大获益
本文为观点综述,讨论风湿科常用糖皮质激素冲击治疗可静脉给药,但现有文献提示口服甲泼尼龙在临床结局和安全性上不劣于静脉给药。将口服甲泼尼龙冲击治疗整合进风湿科实践,可能对患者和社会均带来可观获益。
要点
- 口服甲泼尼龙冲击治疗在临床结局和安全性上不劣于静脉给药。
- 冲击治疗有望降低累积糖皮质激素负荷,已在系统性红斑狼疮和巨细胞动脉炎中获得验证。
- 将口服甲泼尼龙冲击治疗纳入风湿科实践可能对患者和社会均有显著获益。
核心结论
- 口服甲泼尼龙冲击治疗是临床实践中的微调,但可能带来重大获益。
研究设计与样本
- 本文为观点综述,覆盖口服甲泼尼龙冲击治疗的药理学、安全性、患者偏好、可持续性及在风湿科实践中的可能应用。
主要发现
- 当前文献提示口服甲泼尼龙在临床结局和安全性上不劣于静脉给药。
- 冲击治疗有潜力降低累积糖皮质激素负荷,已在系统性红斑狼疮和巨细胞动脉炎中获得验证。
- 风湿科标准实践为静脉给药,但口服甲泼尼龙可作为非劣效选项。
临床怎么用
- 风湿科医生应提高对口服糖皮质激素冲击治疗潜在应用的认识,考虑将其整合进临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucocorticoid pulse therapy is commonly prescribed by rheumatologists worldwide for a wide variety of serious and potentially life-threatening diseases. Pulse therapy also has the potential to lower the cumulative glucocorticoid burden, which has already been proven in systemic lupus erythematosus and giant cell arteritis. The standard practice in rheumatology is to administer this therapy intravenously, but current literature suggests that oral methylprednisolone is a non-inferior option for clinical outcomes and safety. Integrating oral methylprednisolone pulse therapy into rheumatological practice might have considerable benefits, not only for patients but also for society as a whole. In this Viewpoint, we provide a review of oral methylprednisolone pulse therapy covering pharmacology, safety, patient preference, sustainability, and its possible use in rheumatology practice. We aim to increase awareness among rheumatologists of the potential use of oral glucocorticoid pulse therapy as this modest change in clinical practice has major benefits.
引用
- Schenning LCM, van Onna M, Tas SW, et al. Oral glucocorticoid pulse therapy: a modest change in clinical practice with major benefits. Lancet Rheumatol. 2025. PMID: 41418799. doi:10.1016/S2665-9913(25)00321-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。